Evidence map›Paper›PMID 34123401›Full record

ArticleObesity science & practice2021

L-arginine as a potential GLP-1-mediated immunomodulator of Th17-related cytokines in people with obesity and asthma.

Shu-Yi Liao, Angela Linderholm, Megan R Showalter, Ching-Hsien Chen, Oliver Fiehn, Nicholas J Kenyon

Open access · goldAbstract read
In one paragraph

Article in Obesity science & practice, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Shu-Yi LiaoDepartment of Medicine National Jewish Health Denver Colorado USA.ORCID https://orcid.org/0000-0001-9477-3837
Angela LinderholmDivision of Pulmonary, Critical Care, and Sleep Medicine Department of Internal Medicine University of California-Davis Sacramento California USA.
Megan R ShowalterNIH West Coast Metabolomics Center University of California-Davis Davis California USA.
Ching-Hsien ChenDivision of Pulmonary, Critical Care, and Sleep Medicine Department of Internal Medicine University of California-Davis Sacramento California USA.
Oliver FiehnNIH West Coast Metabolomics Center University of California-Davis Davis California USA.
Nicholas J KenyonDivision of Pulmonary, Critical Care, and Sleep Medicine Department of Internal Medicine University of California-Davis Sacramento California USA.
University of California System · USUniversity of California, Davis · USNational Jewish Health · US

Funding

UC Davis Environmental Health Sciences Core CenterP30ES023513 · NIEHS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Irva Hertz-Picciotto · 2015 to 2026
$26.0M
Revisiting ReCHARGE: ECHO Follow up on Middle Childhood and AdolescenceUH3OD023365 · OD · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Deborah Hall Bennett, Irva Hertz-Picciotto · 2018 to 2026
$21.9M
NIEHS NIH HHS P30 ES023513NIH HHS UH3 OD023365
6 · The paper itself

Abstract

Obesity is considered as a risk factor for COVID-19 with insulin resistance and increased production of inflammatory cytokines as likely mechanisms. Glucagon-like peptide-1 (GLP-1) agonists and inhaled nitric oxide are proposed therapeutic approaches to treat COVID-19 because of their broad anti-inflammatory effects. One approach that might augment GLP-1 levels would be dietary supplementation with L-arginine. Beyond cytokines, multiple studies have started to investigate the relationship between new-onset diabetes and COVID-19. In a posthoc analysis of a randomized, placebo-controlled human clinical trial of L-arginine supplementation in people with asthma and predominantly with obesity, the results showed that 12 weeks of continuous L-arginine supplementation significantly decreased the level of IL-21 (

Indexed as

arginineCOVID‐19GLP‐1nitric oxideTh17

Identifiers

PMID34123401
PMCPMC8170586
OpenAlexW3137971452

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.